Last updated on October 2017

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)


Brief description of study

This study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study consists of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.

Clinical Study Identifier: NCT02562235

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

East Carolina University
Greenville, NC United States
2.67miles
  Connect »